Global Cervical Cancer Diagnostic Tests Market Is Expanding Owing To Increasing Incidences Of Cervical Cancer And Growing Awareness Of The Early Diagnosis Of Cervical Cancer

Cervical Cancer Diagnostic Tests Market
Cervical Cancer Diagnostic Tests Market
     
Overview:

The Pap test and HPV test are cervical cancer screening tests that help to find abnormal cells (pre-cancers) in their earliest stage before they have a chance to turn into cervical cancer. They are the best way to detect cervical cancer early, when treatment can be most effective. A Pap test is done by using a speculum and a brush or spatula to collect cells from the cervix. This is an easy, quick test that can be done in the doctor's office.

HPV testing is a lab test that looks for infection by high-risk types of human papillomavirus (HPV) that can lead to pre-cancers and cervical cancer. It is used alone or with the Pap test (called co-testing) in women over 30. Cervical cancer can also be detected by a visual examination of the vagina and rectum using a special magnifying instrument called a colposcope. Imaging tests, such as X-rays, CT scans, MRI and positron emission tomography (PET) can show whether the cancer has spread beyond the cervix.

Market Dynamics:

Increasing partnerships between key players is estimated to augment growth of the global Cervical Cancer Diagnostic Tests Market over the forecast period. For instance, Inovio Pharmaceuticals and Qiagen entered in an extended partnership in February 2021, for developing liquid biopsy-based companion diagnostic products based on NGS (next-generation sequencing) technology. Moreover, high cost of implants is anticipated to restrain growth of the global cervical cancer diagnostic tests for market over the forecast period.

Impact of COVID-19:

COVID-19 was first recognized in China in 2019 and later on it was transmitted to many other countries. The pandemic had affected the economy globally and also led to imposition of lockdowns in several nations. The healthcare sector was severely impacted by the outbreak of the virus. Hospitals were running on full capacity and all resources were used for treating COVID-19 patients.

The In Mexico In-Vitro Diagnostics Market is also witnessing steady growth, primarily due to the increasing prevalence of chronic diseases and the growing demand for point-of-care testing. The market includes various IVD technologies, such as molecular diagnostics, immunoassays, clinical chemistry, and hematology.

The pandemic led to disruptions health services associated with cervical screening and cancer treatments. This affected the growth of the global cervical cancer diagnostic tests for market in a negative manner. However, during the pandemic many organizations devised new approaches for distributing the cervical management and screening processes.

Key Takeaways:

The global Cervical Cancer Diagnostic Tests Market is expected to witness high growth, exhibiting CAGR of 6.2 % over the forecast period, due to increasing technological advancements and product launches.

For instance, Magnetom Free Star, was introduced by Siemens Healthineers in November 2021. This whole-body MRI scanner has been designed to provide better access to magnetic resonance imaging globally.

North America is anticipated to witness significant growth in the global cervical cancer diagnostic tests for market over the forecast period, owing to growing awareness regarding the diagnosis of cervical cancer.

Major players operating in the global Cervical Cancer Diagnostic Tests Market are LCM GENECT Srl, Siemens Healthcare GmbH, BD, Arbor Vita Corporation, Hoffmann-La Roche Ltd, GenomeMe Lab Inc., Abbott, Guided Therapeutics, Inc., Hologic, Inc., Jiangsu Mole Bioscience Co. Ltd., Quest Diagnostics Incorporated, Zilico, Bio-Rad Laboratories, Inc., MobileODT, QIAGEN, Sysmex Corporation, and The Cooper Companies Inc.

Comments

Post a Comment

Popular posts from this blog

Sarcopenia Treatment; Training and Physical Exercise Is Key to Counteract Sarcopenia

Image
Sarcopenia Treatment A primary Sarcopenia Treatment is exercise. Researchers have identified resistance training as the specific form of exercise that is most beneficial to individuals with sarcopenia. At present, resistance exercise, protein supplementation, and vitamin D have been established as the basic treatment of sarcopenia. Recent clinical trials on sarcopenia therapies such as physical exercise, nutraceutical, and pharmaceutical interventions have revealed that exercise is the only effective strategy shown to alleviate sarcopenia. Sarcopenia refers to a loss of muscle mass specifically related to aging. It's normal to lose some muscle mass as people age. Sarcopenia has been defined as an age-related, involuntary loss of skeletal muscle mass and strength. Although aging is the main cause of sarcopenia, some other factors contribute to the loss of muscle mass. Getting little or no physical activity on a regular basis puts people at an increased risk of developing sarcopenia
Read more

Bioresorbable Implants Can Also Help To Prevent Complications And Speed Up The Recovery Process

Image
Bioresorbable Implants Medical implants, either passive for structural support or for diagnosis and therapy with active electronics, are widely used in surgical applications. Although they have shown long-term biocompatibility, their removal imposes physical, biological and economical burdens on patients. To overcome this drawback, implantable devices exhibiting biodegradation in the body have been developed. These implants disappear inside the body after a certain time of use, and can be replaced with natural bone. The resorption of Bioresorbable Implants is driven by hydrolysis of the bonds linking their monomers. The amorphous portions of the polymer degrade first, while the crystalline regions remain intact and provide most of their mechanical strength. The monomers are then broken down into lactic and glycolic acids, which are converted to pyruvate and then processed through the citric acid cycle into water and carbon dioxide. The Bioresorbable Implants Market was valued at US$
Read more

Increasing Developments by Key Players Are Expected To Augment the Growth of the Global Digital Pathology Market

Image
 Digital Pathology Digital Pathology Market , by Product Type (Image Analysis Software, Scanner {Bright Field Scanner, Fluorescence Scanner}, Services {Installation & Integration, Maintenance Services, Consulting Services}), by Therapeutic Area (Oncology, Hematology, Autoimmune Disorder, Dermatology, and Others), by Technology (Immunohistochemistry, ISH & FISH, Immunofluorescence and others) End User (Pharmaceutical & Biotechnology Companies, Diagnostic Labs, Hospital Laboratories, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030. The global Digital Pathology Market is anticipated to reach an estimated value of US$ 884.4 million in 2023 and is projected to grow at a CAGR of 12.2% from 2023 to 2030. Market Overview: Digital pathology refers to the practice of digitizing glass slides containing tissue samples and analyzing them using digital imaging technology
Read more